Gilead Sciences, Inc. has announced a new licensing agreement with the Medicines Patent Pool, a United Nations-backed public health organization, to expand access to bictegravir upon regulatory approval in the U.S. Through the agreement, the Medicines Patent Pool can sub-license rights to bictegravir to generic drug companies in India, China and South Africa to manufacture therapies containing bictegravir for distribution in 116 low- and middle-income countries.

Gilead has also expanded its licensing agreements with Sun Pharmaceutical Industries Limited, Strides Shasun Limited, Mylan Laboratories Limited and SeQuent Scientific Limited to include bictegravir, and products incorporating the compound, for distribution in 116 developing countries.

Bictegravir is an investigational integrase strand transfer inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Gilead has filed a New Drug Application to the U.S. Food and Drug Administration for an investigational, once-daily single tablet regimen containing Bictegravir (50mg) and emtricitabine/tenofovir alafenamide.